Navigation Links
Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Date:7/31/2008

SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present information on platinum resistance at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium on Friday, August 1, in San Diego.

Neela Patel, Ph.D., director of preclinical and translational medicine for Poniard Pharmaceuticals, will present on the topic of "Molecular Mechanisms of Platinum Resistance" at 2:30 p.m. Pacific Time. Jerry McMahon, Ph.D., chairman and chief executive officer, will participate in the symposia's concluding panel discussion at 3:15 p.m. Pacific Time.

"Each year, 300,000 cancer patients in the United States are treated with a platinum-based chemotherapy, and most relapse after initial treatment," said Dr. McMahon. "Therefore, intrinsic or acquired resistance to platinums is a significant treatment issue. Picoplatin, our lead product candidate, was designed to overcome platinum resistance, and we are exploring the use of genetic markers of platinum resistance to optimize patient treatment."

About The Rebecca and John Moores UCSD Cancer Center

The Rebecca and John Moores UCSD Cancer Center seeks to bring the finest minds in treatment and research under one roof to share the latest advances in the oncology field, and to create a fertile atmosphere that promotes networking and collaboration opportunities of benefit to all participants.

Information about the Moores UCSD Cancer Center and the Translational Oncology Symposium can be found at http://cancer.ucsd.edu/symposium/index.asp.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Diego, Calif. (PRWEB) , ... March 01, 2017 ... ... from its annual Marketing Taskforce to join Lajollacooks4u for an exciting evening of ... month. , Approximately 60 team members attended the “Food Truck” corporate cooking challenge, ...
(Date:3/1/2017)... -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the ... sciences industry, today announced the launch of CryoStork SM ... CryoStork SM Next Flight Out is the fastest, ... patients, providing express transportation across the United ... commodities such as sperm, eggs, embryos and reproductive tissues. ...
(Date:3/1/2017)... , March 1, 2017 Genesis Biotechnology ... of biotechnology and research companies, announced that it ... acquisition of PharmOptima. PharmOptima, a ... and Venenum Biodesign in the existing drug development ... of available services, while providing the same high ...
(Date:3/1/2017)... SHANGHAI , March 1, 2017  Luxcel ... based Biotechnology Company and HD Biosciences Co., ... Research Organization (CRO), announced today that they have ... new assay technologies for preclinical drug safety services. ... Luxcel,s state-of-the-art assays and technologies for assessment of ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:1/26/2017)... -- Crossmatch, a leading provider of security and identity management ... fraud, waste and abuse in assistance operations around the ... Disaster Relief conference in Panama City ... foreign assistance organizations throughout Latin America ... largely unacknowledged problem in the foreign assistance and disaster ...
Breaking Biology News(10 mins):